SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-21-040535
Filing Date
2021-08-05
Accepted
2021-08-05 16:31:46
Documents
58
Period of Report
2021-06-30

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT f10q0621_protarathera.htm   iXBRL 10-Q 1011311
2 CERTIFICATION f10q0621ex31-1_protarathera.htm EX-31.1 16064
3 CERTIFICATION f10q0621ex31-2_protarathera.htm EX-31.2 15382
4 CERTIFICATION f10q0621ex32-1_protarathera.htm EX-32.1 9284
  Complete submission text file 0001213900-21-040535.txt   4584014

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE tara-20210630.xsd EX-101.SCH 50099
6 XBRL CALCULATION FILE tara-20210630_cal.xml EX-101.CAL 29511
7 XBRL DEFINITION FILE tara-20210630_def.xml EX-101.DEF 207705
8 XBRL LABEL FILE tara-20210630_lab.xml EX-101.LAB 400782
9 XBRL PRESENTATION FILE tara-20210630_pre.xml EX-101.PRE 219992
10 EXTRACTED XBRL INSTANCE DOCUMENT f10q0621_protarathera_htm.xml XML 591068
Mailing Address 345 PARK AVENUE SOUTH 3RD FLOOR NEW YORK NY 10010
Business Address 345 PARK AVENUE SOUTH 3RD FLOOR NEW YORK NY 10010 646-844-0337
Protara Therapeutics, Inc. (Filer) CIK: 0001359931 (see all company filings)

IRS No.: 204580525 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36694 | Film No.: 211148834
SIC: 2836 Biological Products, (No Diagnostic Substances)